We evaluated the performance of this technology for the assessment, detection, and quantification of biomarkers for AD in NDEVs, including p181-Tau, Aβ, pro-BDNF, and synaptic proteins, retrospectively, in samples from two cohorts of patients with early-stage AD and controls. Here, BDNF is linked to Alzheimer disease.